Menu

FDA Seeks to Block Two Unregulated Stem Cell Clinics

Two patients became legally blind after receiving treatments at the facilities.

May 11, 2018
Jim Daley

FLICKR, FDA

On Wednesday (May 9), the Food and Drug Administration announced that it is requesting injunctions in federal courts against two stem cell clinics, one based in California and another in Florida, that would force them to stop operating. Two former patients are suing the cell shops, saying they went blind after receiving treatments at them, according to The Washington Post.

See “Women Lose Vision After Stem Cell Treatment

“Cell-based regenerative medicine holds significant medical opportunity, but we’ve also seen some bad actors leverage the scientific promise of this field to peddle unapproved treatments that put patients’ health at risk,” says FDA Commissioner Scott Gottlieb in a press release. “In some instances, patients have suffered serious and permanent harm after receiving these unapproved products. In the two cases filed today, the clinics and their leadership have continued to disregard the law and more importantly, patient safety.”

The FDA warned US Stem Cell in Florida and the California Stem Cell Treatment Center that it had “serious concerns” about their practices in August 2017, according to STAT News. In the press release, the FDA says the clinics “did not address the violations” described in the warning letter.

See “Texas Stem Cell Law Opens Door for Controversial Treatments

In a statement, US Stem Cell says it intends “to vigorously defend” the lawsuit. “My entire career has been dedicated to studying and developing treatments utilizing the body’s own natural ability to heal,” says Kristin Comella, the clinic’s chief science officer, in a statement quoted in The Post. “I remain steadfast that no government agency should deprive individuals of their right to harness the cells that exist in their body.”

April 2019

Will Car T Cells Smash Tumors?

New trials take the therapy beyond the blood

Marketplace

Sponsored Product Updates

Application of TruBIOME™ to Increase Mouse Model Reproducibility
Application of TruBIOME™ to Increase Mouse Model Reproducibility
With this application note from Taconic, learn about the effects of the microbiome on reproducibility and predictability and how TruBIOME™ helps researchers generate custom microbiota mouse models!
Getting More Consistent Results by Knowing the Quality of Your Protein
Getting More Consistent Results by Knowing the Quality of Your Protein
Download this guide from NanoTemper to learn how to identify and evaluate the quality of your protein samples!
Myth Busting: The Best Way to Use Pure Water in the Lab
Myth Busting: The Best Way to Use Pure Water in the Lab
Download this white paper from ELGA LabWater to learn about the role of pure water in the laboratory and the advantages of in-house water purification!
Shimadzu's New Nexera UHPLC Series with AI and IoT Enhancements Sets Industry Standard for Intelligence, Efficiency and Design
Shimadzu's New Nexera UHPLC Series with AI and IoT Enhancements Sets Industry Standard for Intelligence, Efficiency and Design
Shimadzu Corporation announces the release of the Nexera Ultra High-Performance Liquid Chromatograph series, incorporating artificial intelligence as Analytical Intelligence, allowing systems to detect and resolve issues automatically. The Nexera series makes lab management simple by integrating IoT and device networking, enabling users to easily review instrument status, optimize resource allocation, and achieve higher throughput.